Skip to content

Author

X. Leleu

We have 2 of 163 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Oct 2026

MK-4002, a B-cell maturation antigen-targeting T-cell engager, in relapsed or refractory multiple myeloma: a first-in-human, open-label, phase 1 study.

BACKGROUND The optimal treatment strategy for relapsed or refractory multiple myeloma remains unclear. This first-in-human study aimed to evaluate the safety, preliminary activity, and pharmacokinetics of the trispecific B-cell maturation antigen-targeting T-cell engager MK-4002 in relapsed or refractory multiple myelo...

S. Madan, Caitlin L. Costello, B. Lipe et al. · 1 citation
Open access Sep 2026

Inflammatory bone marrow microenvironment impairs the therapeutic effect of daratumumab-lenalidomide in multiple myeloma

An NF-κB-associated inflammatory axis underlying poor DR response is underscores an NF-κB-associated inflammatory axis underlying poor DR response and suggests that targeting inflammatory pathways a potential therapeutic avenue warranting further investigation.

Wen-Wen Cheng, S. Gaggero, Lama Hasan Bou Issa et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.